Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 2, 2007, Pages 334-341

  Martin, André Guy ^a   Roy, Jean ^a   Beaulieu, Luc ^a,b   Pouliot, Jean ^c   Harel, François ^b   Vigneault, Eric ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

High activity; Inverse planning; Iodine; Outcome; Prostate brachytherapy; Seed implants; Toxicity

Indexed keywords

ALGORITHMS; IODINE; PATIENT TREATMENT; SIMULATED ANNEALING; TOXICITY;

GENITOURINARY SYMPTOMS (GU); INVERSE PLANNING; PROSTATE BRACHYTHERAPY;

IMPLANTS (SURGICAL);

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALGORITHM; ARTICLE; BRACHYTHERAPY; CANADA; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE BRACHYTHERAPY; PROSTATE CARCINOMA; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT PLANNING;

EID: 33846347647     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.08.042     Document Type: Article

References (30)

1. Holm H.H., Juul N., Pedersen J.F., et al. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. 1983. J Urol 167 (2002) 985-989
2. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
3. Sloboda R.S., Pedersen J.E., Hanson J., et al. Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol 68 (2003) 295-297
4. Narayana V., Troyer S., Evans V., et al. Randomized trial of high- and low-source strength (125)I prostate seed implants. Int J Radiat Oncol Biol Phys 61 (2005) 44-51
5. Sloboda R.S., Pedersen J.E., and Halperin R. Is there a preferred strength for regularly spaced 125I seeds in inverse-planned prostate implants?. Int J Radiat Oncol Biol Phys 55 (2003) 234-244
6. Pouliot J., Tremblay D., Roy J., et al. Optimization of permanent 125I prostate implants using fast simulated annealing. Int J Radiat Oncol Biol Phys 36 (1996) 711-720
7. Taschereau R., Roy J., and Pouliot J. Monte Carlo simulations of prostate implants to improve dosimetry and compare planning methods. Med Phys 26 (1999) 1952-1959
8. Taschereau R., Pouliot J., Roy J., et al. Seed misplacement and stabilizing needles in transperineal permanent prostate implants. Radiother Oncol 55 (2000) 59-63
9. Beaulieu L., Archambault L., Aubin S., et al. The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs. Int J Radiat Oncol Biol Phys 58 (2004) 1298-1308
10. Roy J., Pouliot J., and Taschereau R. Permanent transperineal prostate implants performed under local anesthesia. Int J Radiat Oncol Biol Phys 42 (1998) 296
11. Wallner K. Prostate brachytherapy under local anesthesia; lessons from the first 600 patients. Brachytherapy 1 (2002) 145-148
12. Wallner K., Roy J., and Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 32 (1995) 465-471
13. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
14. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45 (1999) 59-67
15. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
16. Beyer D.C., Thomas T., Hilbe J., et al. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2 (2003) 77-84
17. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
18. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 1261-1266
19. Battermann J.J., Boon T.A., and Moerland M.A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71 (2004) 23-28
20. Ragde H., Blasko J.C., Grimm P.D., et al. Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up. Semin Surg Oncol 13 (1997) 438-443
21. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48 (2000) 111-117
22. Nag S., Ciezki J.P., Cormack R., et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 51 (2001) 1422-1430
23. Cesaretti J.A., Stone N.N., and Stock R.G. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 1085-1092
24. Merrick G.S., Butler W.M., Wallner K.E., et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 979-985
25. Kang S.K., Chou R.H., Dodge R.K., et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys 50 (2001) 937-945
26. Stone N.N., and Stock R.G. Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive seed implantation for localized prostate cancer. Mol Urol 3 (1999) 239-244
27. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
28. Moerland M.A., and Battermann J.J. Randomized trial of high- and low-source strength (125)I prostate seed implants: In regard to Narayana, et al. (Int J Radiat Oncol Biol Phys 2005;61:44-51). [letter]. Int J Radiat Oncol Biol Phys 62 (2005) 941-942
29. Beaulieu L., Varfalvy N., Aubin N., et al. Clinical validation of a new inverse planning algorithm for permanent prostate implant-ESTRO 23. Abstracts of the European Society for Therapeutic Radiology and Oncology meeting. Amsterdam, The Netherlands, October 24-28, 2004. Radiother Oncol 73 Suppl 1 (2004) S1-S497
30. Lee L.N., Stock R.G., and Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 444-452